Flaxman, A, Marchevsky, NG, Jenkin, D, Aboagye, J, Aley, PK, Angus, B, Belij-Rammerstorfer, S, Bibi, S, Bittaye, M, Cappuccini, F, Cicconi, P, Clutterbuck, EA, Davies, S, Dejnirattisai, W, Dold, C, Ewer, KJ, Folegatti, PM, Fowler, J, Hill, AVS, Kerridge, S et al, Minassian, AM, Mongkolsapaya, J, Mujadidi, YF, Plested, E, Ramasamy, MN, Robinson, H, Sanders, H, Sheehan, E, Smith, H, Snape, MD, Song, R, Woods, D, Screaton, G, Gilbert, SC, Voysey, M, Pollard, AJ, Lambe, T, Oxford COVID Vaccine Trial group, and Tahmasebi, F (2021) Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, 398 (10304). pp. 981-990. ISSN 0140-6736